Fortune Financial Advisors LLC Buys 209 Shares of STERIS plc (NYSE:STE)

Fortune Financial Advisors LLC raised its position in STERIS plc (NYSE:STE) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,231 shares of the medical equipment provider’s stock after acquiring an additional 209 shares during the period. STERIS comprises approximately 1.1% of Fortune Financial Advisors LLC’s holdings, making the stock its 27th largest holding. Fortune Financial Advisors LLC’s holdings in STERIS were worth $1,590,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Millburn Ridgefield Corp bought a new position in STERIS in the third quarter valued at approximately $25,000. Catalyst Capital Advisors LLC acquired a new stake in STERIS during the 3rd quarter valued at $25,000. 1832 Asset Management L.P. bought a new stake in shares of STERIS during the 1st quarter worth about $25,000. Global Wealth Management Investment Advisory Inc. acquired a new position in shares of STERIS in the third quarter valued at approximately $49,000. Finally, NBC Securities Inc. acquired a new stake in shares of STERIS during the third quarter worth $50,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. KeyCorp assumed coverage on shares of STERIS in a report on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price target on the stock. Stephens reaffirmed an “overweight” rating and set a $250.00 price target on shares of STERIS in a research report on Friday, February 9th. JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Thursday, February 8th. Finally, TheStreet upgraded shares of STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $239.60.

STERIS Stock Down 0.4 %

STERIS stock traded down $0.83 during trading hours on Monday, hitting $212.65. The stock had a trading volume of 616,334 shares, compared to its average volume of 426,775. The company has a quick ratio of 1.49, a current ratio of 2.43 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average price is $227.00 and its 200-day moving average price is $218.53. STERIS plc has a 12-month low of $180.54 and a 12-month high of $254.00. The stock has a market capitalization of $21.01 billion, a P/E ratio of 37.24 and a beta of 0.79.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.17 by $0.05. The company had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.35 billion. STERIS had a net margin of 10.48% and a return on equity of 13.67%. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. Equities research analysts anticipate that STERIS plc will post 8.67 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Friday, February 23rd were given a $0.52 dividend. The ex-dividend date was Thursday, February 22nd. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.98%. STERIS’s payout ratio is currently 36.43%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.